Protara Therapeutics (1KPA) Price & Analysis

5 Followers

1KPA Stock Chart & Stats

€3.22

-€0.02(-0.54%)

At close: Jul 24 4:00 PM EDT

€3.22

-€0.02(-0.54%)

Day’s Range― - ―

52-Week Range€1.94 - €6.50

Previous CloseN/A

Volume0.00

Average Volume (3M)130.00

Market Cap

€122.09M

Enterprise Value€93.30M

Total Cash (Recent Filing)€17.08M

Total Debt (Recent Filing)€2.75M

Price to Earnings (P/E)―

Beta0.93

Next Earnings

Oct 29, 2026

EPS Estimate

-0.33

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.36

Shares Outstanding59,095,490

10 Day Avg. Volume92

30 Day Avg. Volume130

Financial Highlights & Ratios

PEG Ratio0.10

Price to Book (P/B)1.16

Price to Sales (P/S)0.00

P/FCF Ratio-4.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€21.36

Price Target Upside563.28% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-1.16

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Financial LeverageVery low leverage limits interest and repayment burdens, giving Protara greater flexibility to direct capital toward research and development. This strengthens financial resilience relative to a debt-funded biotech, although it does not eliminate the need to finance continuing operating losses.

Unmet-Need Therapeutic FocusFocusing on cancer and rare diseases with significant unmet medical need can support meaningful clinical and commercial opportunities if development succeeds. These areas may also provide a durable rationale for investment in differentiated therapies rather than commoditized healthcare offerings.

Pipeline OptionalityStudying TARA-002 across oncology and lymphatic malformations gives Protara more than one potential application for its lead program. Multiple development paths can broaden eventual opportunity and provide strategic optionality, although each remains investigational and dependent on clinical progress.

Bears Say

No Commercial RevenueThe absence of revenue means Protara has not yet demonstrated commercial product demand or an operating revenue base. Until a program reaches approval and market adoption, the company remains dependent on development outcomes and external financing to sustain its business.

Widening Net LossesWidening losses indicate that spending is increasing faster than the company is generating economic returns, consistent with rising cost intensity and no operating leverage. Persistent losses can reduce equity capital over time and increase the resources required before the pipeline can support itself.

Increasing Cash BurnIncreasing negative free cash flow raises the amount of capital Protara must obtain to continue research and corporate operations. Sustained burn can accelerate financing needs and dilute existing shareholders, while also increasing the risk that development priorities must be adjusted.

Protara Therapeutics News

Protara Therapeutics management to meet with Cantor

Meeting to be held in New York on October 13 hosted by Cantor. Published first on TheFly –...

11d ago

TARA

Protara’s TARA-002 Moves Into Pivotal Bladder Cancer Trial: What Investors Should Watch

Protara Therapeutics, Inc. ($TARA) announced an update on their ongoing clinical study. Protara Therapeutics, Inc. is running a...

2M ago

TARA

Protara: Strategic Trial Redesign and Strong TARA-002 Profile Support Buy Rating with Unchanged $27 Price Target

In a report released today, Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on Protara Therapeutics,...

2M ago

TARA

Protara Therapeutics: Advancing Pipeline and Strong Cash Runway Underpin Boris Peaker’s Buy Rating and $25 Price Target

JonesTrading analyst Boris Peaker has maintained their bullish stance on TARA stock, giving a Buy rating yesterday. Boris...

2M ago

TARA

Protara Therapeutics: Strategic Trial Shift and Strong Cash Runway Support Buy Rating Despite Price Target Cut to $20 From $26

Analyst Charles Zhu of LifeSci Capital maintained a Buy rating on Protara Therapeutics, reducing the price target to...

2M ago

TARA

Protara Therapeutics reports Q2 EPS (36c), consensus (31c)

“In the second quarter, we strengthened our late-stage pipeline through continued operational execution, positioning us for multiple important...

2M ago

TARA

Is TARA a Buy, Before Earnings?

Protara Therapeutics, Inc. (TARA) is scheduled to report 2nd quarter earnings on 07/30/2026. Regarding Q2 estimates, Wall Street...

3M ago

TARA

uniQure, Protara, Abeona, Cerebras, Verisign Insider Shake-Up

Insiders have been trading these 5 stocks: (($QURE)), (($TARA)), (($ABEO)), (($CBRS)) and (($VRSN)). Here is a breakdown of...

4M ago

ABEO

CBRS

Protara Therapeutics Announces Key Medical Leadership Transition

Protara Therapeutics ( ($TARA) ) has issued an announcement. On June 26, 2026, Protara Therapeutics, Inc. announced that...

4M ago

TARA

Protara Therapeutics Stockholders Approve Governance and Share Increases

Protara Therapeutics ( ($TARA) ) just unveiled an announcement. Protara Therapeutics held its Annual Meeting of Stockholders on...

4M ago

TARA

Protara Therapeutics price target raised to $28 from $25 at Oppenheimer

Oppenheimer raised the firm’s price target on Protara Therapeutics (TARA) to $28 from $25 and keeps an Outperform...

5M ago

TARA

Peaker Reiterates Buy on TARA-002 After Strong STARBORN-2 Data, Sets $25 Price Target on Accelerated Approval Potential

JonesTrading analyst Boris Peaker reiterated a Buy rating on Protara Therapeutics yesterday and set a price target of...

5M ago

TARA

Unusually active option classes on open May 15th

Unusual total active option classes on open include: Protara Therapeutics (TARA), Honeywell (HON), PowerShares KBW Bank Portfolio (KBWB),...

5M ago

AGQ

CSX

Protara announces updated 12-month data from Cohort A of ADVANCED-2 trial

Protara Therapeutics (TARA) announced updated 12-month data from Cohort A of the ongoing Phase 2 open-label ADVANCED-2 trial...

5M ago

TARA

1KPA FAQ

What was Protara Therapeutics’s price range in the past 12 months?

Protara Therapeutics lowest stock price was €1.94 and its highest was €6.50 in the past 12 months.

What is Protara Therapeutics’s market cap?

Protara Therapeutics’s market cap is €122.09M.

When is Protara Therapeutics’s upcoming earnings report date?

Protara Therapeutics’s upcoming earnings report date is Oct 29, 2026 which is in 10 days.

How were Protara Therapeutics’s earnings last quarter?

Protara Therapeutics released its earnings results on Aug 11, 2026. The company reported -€0.321 earnings per share for the quarter, missing the consensus estimate of -€0.29 by -€0.03.

Is Protara Therapeutics overvalued?

According to Wall Street analysts Protara Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Protara Therapeutics pay dividends?

Protara Therapeutics does not currently pay dividends.

What is Protara Therapeutics’s EPS estimate?

Protara Therapeutics’s EPS estimate is -0.33.

How many shares outstanding does Protara Therapeutics have?

Protara Therapeutics has 59,095,490 shares outstanding.

What happened to Protara Therapeutics’s price movement after its last earnings report?

Protara Therapeutics reported an EPS of -€0.321 in its last earnings report, missing expectations of -€0.29. Following the earnings report the stock price went down -0.296%.

Which hedge fund is a major shareholder of Protara Therapeutics?

Currently, no hedge funds are holding shares in DE:1KPA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Protara Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-41.72%

Trailing 12-Months

Asset Growth

12.21%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Protara Therapeutics

Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.

Protara Therapeutics (1KPA) Earnings & Revenues

Historic Earnings Reports

1KPA Stock 12 Month Forecast

Average Price Target

€21.36

▲(563.28% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","7":"€7","13":"€13","19":"€19","25":"€25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24.02740179,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€24.03</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.35769048,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€21.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.7980754,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€17.80</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,7,13,19,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.544,4.196569368461539,5.849138736923077,7.5017081053846155,9.154277473846154,10.806846842307692,12.45941621076923,14.111985579230769,15.764554947692307,17.417124316153846,19.069693684615384,20.722263053076922,22.37483242153846,{"y":24.02740179,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.544,3.99120696,5.43841392,6.885620879999999,8.33282784,9.7800348,11.22724176,12.674448720000001,14.12165568,15.568862639999999,17.016069599999998,18.46327656,19.91048352,{"y":21.35769048,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.544,3.7173904153846156,4.890780830769231,6.064171246153846,7.237561661538461,8.410952076923076,9.584342492307693,10.757732907692308,11.931123323076923,13.104513738461538,14.277904153846153,15.451294569230768,16.624684984615385,{"y":17.7980754,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.58,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.36,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.35,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.44,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.8,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.1,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.28,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.216,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.812,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.14,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.408,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.132,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.544,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >